Michael Saylor, executive chairman of Strategy, believes Bitcoin has bottomed below $60,000 and anticipates it will rise above $100,000, though without a set timeline. He forecasts annual growth of 20-30% over the next 20 years, driven by factors like favorable regulation, banking adoption, and digital credit development. Saylor views Bitcoin as a scarce digital asset gaining value amid technological shifts, supported by Strategy's large Bitcoin holdings of 848,250 BTC. Despite optimism, market indicators and prediction markets remain cautious, and Strategy faces potential stock index exclusion risks that could impact investment flows.
Bitcoin's outlook is discussed with optimism in the news, here is Pluang's market snapshot as of Oct 15, 2026 01:31 WIB: Among 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable price changes include FIL at Rp19.561 with a -4.59% change and a typical hold time of 99 days, SUSHI at Rp4.065 down 4.25% with 102 days hold, and THETA at Rp3.535 down 4.15% but with 100% buy order activity and a 78-day hold time.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
